uniQure reports early data from AMT-260 epilepsy gene therapy trial
Tweet Send to a Friend
uniQure N.V. (NASDAQ: QURE) released preliminary six-month data from the first cohort of its Phase I/IIa clinical trial of AMT-260 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
